Key statistics
As of last trade, Palatin Technologies Inc (PTN:ASQ) traded at 0.9654, 41.97% above the 52 week low of 0.68 set on Sep 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.94 |
---|---|
High | 0.9745 |
Low | 0.92 |
Bid | 0.9595 |
Offer | 0.9654 |
Previous close | 0.9385 |
Average volume | 202.92k |
---|---|
Shares outstanding | 19.55m |
Free float | 18.86m |
P/E (TTM) | -- |
Market cap | 18.35m USD |
EPS (TTM) | -1.98 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 16:05 GMT.
More ▼
- Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results
- Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024
- Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024
- Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
- Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium
- Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium
- Palatin Receives Notice of Non-Compliance from NYSE American
- Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
- Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results
- Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
More ▼